NeuroBo Pharmaceuticals (NRBO) News Today $2.03 +0.05 (+2.53%) (As of 12/31/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period MTVA: NeuroBo Becomes MetaVia; Topline Results for Phase 2a Trial of DA-1241 in MASH Expected in December 2024…December 4, 2024 | msn.comNeuroBo Pharmaceuticals Rebrands as MetaVia: Strategic Positioning and Growth Potential Highlighted in Buy Rating by Jason McCarthyNovember 21, 2024 | markets.businessinsider.comNeuroBo Pharmaceuticals Rebrands Amidst Strategic ChangesNovember 19, 2024 | markets.businessinsider.comNeuroBo Pharmaceuticals announces relignment, change nameNovember 19, 2024 | markets.businessinsider.comNeuroBo Pharmaceuticals Announces Strategic Realignment Ahead of Important Clinical Milestones with Name Change to MetaVia - Reflecting the Company's Focus on Cardiometabolic DiseasesNovember 18, 2024 | prnewswire.comNRBO: Topline Results for Phase 2a Trial of DA-1241 in MASH Expected in December 2024November 13, 2024 | msn.comNeuroBo Pharmaceuticals to Participate in Investor Conferences in NovemberNovember 13, 2024 | prnewswire.comNeuroBo Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate UpdateNovember 7, 2024 | prnewswire.comNeuroBo Pharmaceuticals Completes Last Patient Last Visit in Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASHNovember 4, 2024 | prnewswire.comNeuroBo Pharmaceuticals (NASDAQ:NRBO) Stock Quotes, Forecast and News SummaryOctober 4, 2024 | benzinga.comNRBO: Positive SAD Part 1 Data; MAD Part 2 Results Expected in 1Q25…October 2, 2024 | msn.comNeuroBo Pharmaceuticals to Participate in Investor Conferences in OctoberOctober 1, 2024 | prnewswire.comNeuroBo Pharma Announces Positive Results From Phase 1 Trial Of DA-1726 In Obesity TreatmentSeptember 30, 2024 | markets.businessinsider.comWe're A Little Worried About NeuroBo Pharmaceuticals' (NASDAQ:NRBO) Cash Burn RateSeptember 30, 2024 | finance.yahoo.comNeuroBo Pharmaceuticals Announces Positive Top-Line Data From the SAD Part 1 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of ObesitySeptember 30, 2024 | prnewswire.comNeuroBo to Participate in the H.C. Wainwright 26th Annual Global Investment ConferenceSeptember 3, 2024 | prnewswire.comNRBO: Data from Part 1 of Phase 1 Trial of DA-1726 in 3Q24…August 21, 2024 | msn.comBuy Rating for NeuroBo Pharmaceuticals Based on Financial Stability and Promising Developmental PipelineAugust 16, 2024 | markets.businessinsider.comNeuroBo concludes subject enrolment in SAD portion of obesity treatment trialAugust 15, 2024 | finance.yahoo.comNeuroBo Pharmaceuticals, Inc. Q2 Loss Increases, Misses EstimatesAugust 14, 2024 | markets.businessinsider.comNeuroBo Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Corporate UpdateAugust 14, 2024 | prnewswire.comNeuroBo Pharmaceuticals Completes Enrollment of the SAD Part 1 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of ObesityAugust 13, 2024 | prnewswire.comBuy Rating on NeuroBo Pharmaceuticals: Strategic Alliances and Market Differentiation PotentialAugust 8, 2024 | markets.businessinsider.comNeuroBo Pharma In Agreement With Dong-A ST And ImmunoForge To Develop DA-1726 To Treat ObesityAugust 6, 2024 | markets.businessinsider.comNeuroBo Pharmaceuticals Announces Joint Research Agreement, Together with Dong-A ST and ImmunoForge to Develop a Long-Acting Once-Monthly Formulation of DA-1726 for the Treatment of ObesityAugust 6, 2024 | prnewswire.comNeuroBo licenses diabetic neuropathy drug to MThera PharmaAugust 1, 2024 | investing.comNeuroBo Enters License Agreement With MThera For NB-01 - Quick FactsJuly 30, 2024 | markets.businessinsider.comNeuroBo Pharmaceuticals Announces Exclusive License Agreement with MThera Pharma for NB-01July 30, 2024 | prnewswire.comNeuroBo Pharmaceuticals to Present at the Emerging Growth Conference in JulyJuly 11, 2024 | prnewswire.comHuge Insider Buying at a Warren Buffett Pick and 5 Other StocksJune 30, 2024 | 247wallst.comNeuroBo Pharmaceuticals Doses First Patient in the MAD Part 2 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of ObesityJune 26, 2024 | prnewswire.comNeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO) Major Shareholder St Co. Ltd Dong-A Acquires 2,544,530 SharesJune 26, 2024 | insidertrades.comNeuroBo Pharmaceuticals Announces the Closing of up to $70 Million Concurrent Private Placement and Registered Direct Offering Priced At-the-Market Under Nasdaq RulesJune 25, 2024 | prnewswire.comNeuroBo Pharmaceuticals Announces up to $70 Million Concurrent Private Placement and Registered Direct Offering Priced At-the-Market Under Nasdaq RulesJune 24, 2024 | prnewswire.comNeuroBo Pharmaceuticals' DA-1726 Demonstrated Superiority in Weight Loss, Retention of Lean Body Mass, and Lipid-Lowering Effects Compared to Survodutide, in Pre-Clinical ModelsJune 22, 2024 | prnewswire.comNRBO: Preclinical Data on DA-1241 with Semaglutide to be Presented at EASL Congress 2024May 28, 2024 | finance.yahoo.comNRBO: Preclinical Data on DA-1241 with Semaglutide to be Presented at EASL Congress 2024May 28, 2024 | finance.yahoo.comNeuroBo Pharma Reveals Positive Pre-clinical Data For DA -1241 In Combination In Liver FibrosisMay 22, 2024 | markets.businessinsider.comNeuroBo says DA-1241, Wegovy combo shows potential in treating MASHMay 22, 2024 | msn.comNeuroBo Pharmaceuticals Stock Slides Despite Animal Study Showing Wegvoy, Liver Fibrosis SuccessMay 22, 2024 | msn.comNeuroBo Pharmaceuticals' DA-1241 in Combination with Semaglutide Improves Liver Fibrosis and Demonstrates Additive Hepatoprotective Effects in Pre-Clinical MASH Models Compared to Either Treatment, AloneMay 22, 2024 | prnewswire.comBuy Rating Affirmed for NeuroBo Pharmaceuticals on Promising Obesity and MASH Drug DevelopmentsMay 18, 2024 | markets.businessinsider.comMaxim Group Initiates Coverage of NeuroBo Pharmaceuticals (NRBO) with Buy RecommendationMay 9, 2024 | msn.comNRBO Stock Earnings: NeuroBo Pharmaceuticals Misses EPS for Q1 2024May 9, 2024 | investorplace.comNeuroBo Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate UpdateMay 9, 2024 | prnewswire.comNeuroBo to Present Latest Pre-Clinical Data on Cardiometabolic Assets, DA-1241 and DA-1726, Targeting MASH and Obesity, at Scientific Conferences in JuneApril 30, 2024 | prnewswire.comNRBO: First Patient Dosed in Phase 1 Trial of DA-1726 for the Treatment of Obesity…April 23, 2024 | finance.yahoo.comNeuroBo Pharmaceuticals Doses First Patient in Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of ObesityApril 17, 2024 | finance.yahoo.comNeuroBo Pharmaceuticals Doses First Patient in Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of ObesityApril 17, 2024 | prnewswire.comNeuroBo Pharmaceuticals Inc NRBOApril 5, 2024 | morningstar.com Get NeuroBo Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for NRBO and its competitors with MarketBeat's FREE daily newsletter. Email Address Grab This Altcoin Before Trump's Crypto Announcement (Ad)Under-the-Radar Crypto Could Soar by Jan. 20th Investors in the know could bank HUGE profits! Click HERE to access this free report NRBO Media Mentions By Week NRBO Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. NRBO News Sentiment▼0.000.65▲Average Medical News Sentiment NRBO News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. NRBO Articles This Week▼01▲NRBO Articles Average Week Get NeuroBo Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for NRBO and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Reviva Pharmaceuticals News Fortress Biotech News Kronos Bio News Gain Therapeutics News RAPT Therapeutics News Shattuck Labs News Spero Therapeutics News Virios Therapeutics News Mural Oncology News FibroGen News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:NRBO) was last updated on 1/2/2025 by MarketBeat.com Staff From Our Partners3 CENT Crypto to Explode December 16th?Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTSLA *BANG* incoming (bullet in the chamber rn)I just pinpointed 5 dirt-cheap stocks that could soar the second the shot goes off. Thanks to Donald Trump’...StocksToTrade | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementGrab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which ...Crypto 101 Media | SponsoredThe Next Big Thing in AI: Musk’s Secret SupplierWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NeuroBo Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share NeuroBo Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
